Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole in Children and Adolescents With Autistic Disorder
NCT00337571Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jun 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aripiprazole in Autism Spectrum Disorder (ASD) (4 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Autistic Behavior Checklist Irritability Subscale at 8 weeks. Started Jun 2006; status: completed.
02
Drugs
aripiprazole
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT00337571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00337571.